Wenemea
The startup develops a neurological screening device that monitors chemotherapy-induced peripheral neuropathy in breast cancer patients. This technology enables earlier intervention and personalized medication adjustments, enhancing patient quality of life during treatment.
- Digital Health
- Medical Devices
Funding
Raised to date
$60KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chemotherapy-induced peripheral neuropathy (CIPN) affects a significant portion of breast cancer patients, leading to diminished quality of life. Current methods for detecting and monitoring CIPN often lack the sensitivity needed for early intervention and personalized treatment adjustments.
Solution
This startup offers a neurological screening device designed to monitor CIPN in breast cancer patients undergoing chemotherapy. The device aims to provide more sensitive and frequent monitoring compared to traditional methods, enabling earlier detection of nerve damage. By identifying CIPN early, clinicians can make timely adjustments to medication regimens and implement interventions to mitigate the severity of symptoms. This proactive approach supports personalized treatment strategies and aims to improve the overall quality of life for patients during cancer treatment.
Target Audience
The primary target audience includes oncologists, neurologists, and other healthcare providers involved in the care of breast cancer patients undergoing chemotherapy, as well as the patients themselves.
Features
- Neurological screening device for monitoring peripheral neuropathy.
- Designed specifically for breast cancer patients undergoing chemotherapy.
- Aims to enable earlier detection of CIPN compared to traditional methods.